698 filings
Page 22 of 35
6-K
mif6ekl5 ne8x0be
24 Apr 17
RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D
12:00am
6-K
0u36qsvo
20 Apr 17
RedHill Biopharma Announces Peer-Reviewed Publication of the Positive YELIVA® Phase I Study Results in Advanced Solid Tumors
12:00am
6-K
hnn270q70l 2gu859km
19 Apr 17
RedHill Biopharma to Host R&D Day on BEKINDA® for Acute Gastroenteritis and IBS-D
12:00am
6-K
snldo406yh90zkjz
18 Apr 17
Current report (foreign)
12:00am
6-K
6o26i01 6bw6yoodqo
13 Apr 17
RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT® for Migraines in Luxembourg
12:00am
6-K
k5zudjd1xqlo3rvvk co
5 Apr 17
Current report (foreign)
12:00am
6-K
46xos
4 Apr 17
RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma
12:00am
6-K
euytvj3p tyt122
3 Apr 17
Current report (foreign)
12:00am
6-K
n4n qkth5zky
30 Mar 17
RedHill Biopharma to Present at BioCentury Future Leaders in the Biotech Industry Conference
12:00am
6-K
9jmv7hh
29 Mar 17
Current report (foreign)
12:00am
6-K
xp86nqkkbb xh
22 Mar 17
RedHill Biopharma to Present at the 2017 MAP Conference
12:00am
6-K
hr8qjnywhywso70lab
21 Mar 17
RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease
12:00am
6-K
if4hrbd
13 Mar 17
RedHill Biopharma to Present at the BIO-Europe Spring 2017 Conference
12:00am
6-K
jwb9o8nn
7 Mar 17
Current report (foreign)
12:00am
6-K
lyf6dr6lq t0yvsakz
23 Feb 17
RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results
12:00am
6-K
mg30 ccymlhy0zxjth
23 Feb 17
RedHill Biopharma Announces Availability of Its Annual Report on Form 20-F Through Its Website
12:00am
6-K
6fgyro4pj5h5kei kn
21 Feb 17
RedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis
12:00am
6-K
c6qs1c8d
16 Feb 17
Current report (foreign)
12:00am
6-K
s5873r fmxkz40g1k4t8
13 Feb 17
RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis
12:00am
6-K
rf28h
6 Feb 17
RedHill Biopharma to Present at the BIO CEO & Investor Conference
12:00am